Publications

Detailed Information

Variants in hormone-related genes and the risk of biliary tract cancers and stones: a population-based study in China

DC Field Value Language
dc.contributor.authorPark, Sue K.-
dc.contributor.authorAndreotti, Gabriella-
dc.contributor.authorSakoda, Lori C.-
dc.contributor.authorGao, Yu-Tang-
dc.contributor.authorChen, Jinbo-
dc.contributor.authorRosenberg, Philip S.-
dc.contributor.authorWang, Bing-Sheng-
dc.contributor.authorZhang, Bai-He-
dc.contributor.authorChanock, Stephen-
dc.contributor.authorHsing, Ann W.-
dc.contributor.authorYeager, Meredith-
dc.contributor.authorHan, Tian-Quan-
dc.contributor.authorShen, Ming-Chang-
dc.contributor.authorChen, Bingshu E.-
dc.contributor.authorRashid, Asif-
dc.date.accessioned2012-06-08T07:48:28Z-
dc.date.available2012-06-08T07:48:28Z-
dc.date.issued2009-04-
dc.identifier.citationCARCINOGENESIS; Vol.30 4; 606-614ko_KR
dc.identifier.issn0143-3334-
dc.identifier.urihttps://hdl.handle.net/10371/76926-
dc.description.abstractBiliary tract cancers, encompassing gallbladder, extrahepatic bile duct and ampulla of Vater cancers, are uncommon but often fatal malignancies. Hormone-related factors, including parity, oral contraceptive use, obesity, and gallstones, have been implicated in the etiology of these cancers. To further clarify the role of hormones in biliary tract cancers and biliary stones, we genotyped 18 single-nucleotide polymorphisms (SNPs) in nine genes involved in steroid hormone biosynthesis, metabolism and transport in a population-based case-control study in Shanghai, China. This study included subjects who completed an interview and provided blood, which totaled 411 biliary tract cancer and 893 biliary stone patients and 786 healthy Shanghai residents. The CYP1A1 IVS1 + 606 (rs2606345) T allele was associated with gallbladder [odds ratio (OR) = 2.0, 95% confidence interval (CI), 1.3-3.0] and bile duct cancers (OR = 1.8, 95% CI = 1.1-3.1), whereas the CYP1A1 Ex7 + 131 (rs1048943) G allele was associated with ampulla of Vater cancer (OR = 2.9, 95% CI = 1.5-5.4). After taking into account multiple comparisons for SNPs within each gene, CYP1A1 was significantly associated with gallbladder (P = 0.004) and ampulla of Vater cancers (P = 0.01), but borderline with bile duct cancer (P = 0.06). The effect of CYP1A1 IVS1 + 606 on gallbladder cancer was more pronounced among non-obese (body mass index < 23) (OR = 3.3, 95% CI = 1.8-6.1; P interaction = 0.001). Among women taking oral contraceptives, the effect of SHBG Ex8 + 6 (rs6259) on gallbladder cancer (OR = 6.7, 95% CI = 2.2-20.5; P interaction = 0.001) and stones (OR = 2.3, 95% CI = 1.1-4.9; P-interaction = 0.05) was statistically significant. Our findings suggest that common variants in hormone-related genes contribute to the risk of biliary tract cancers and stones, possibly by modulating hormone metabolism.ko_KR
dc.language.isoenko_KR
dc.publisherOXFORD UNIV PRESSko_KR
dc.titleVariants in hormone-related genes and the risk of biliary tract cancers and stones: a population-based study in Chinako_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor박수경-
dc.identifier.doi10.1093/carcin/bgp024-
dc.citation.journaltitleCARCINOGENESIS-
dc.description.citedreferenceHsing AW, 2008, CANCER RES, V68, P6442, DOI 10.1158/0008-5472.CAN-08-0444-
dc.description.citedreferenceHsing AW, 2008, BRIT J CANCER, V99, P811, DOI 10.1038/sj.bjc.6604616-
dc.description.citedreferenceHsing AW, 2008, INT J CANCER, V122, P1849, DOI 10.1002/ijc.23251-
dc.description.citedreferenceHsing AW, 2007, BRIT J CANCER, V97, P1577, DOI 10.1038/sj.bjc.6604047-
dc.description.citedreferenceChen CH, 2006, J GASTROEN HEPATOL, V21, P1737, DOI 10.1111/j.1440-1746.2006.04381.x-
dc.description.citedreferenceRosenberg PS, 2006, STAT MED, V25, P3134, DOI 10.1002/sim.2407-
dc.description.citedreferenceHou LF, 2006, INT J CANCER, V118, P2847, DOI 10.1002/ijc.21708-
dc.description.citedreferenceSakoda LC, 2006, CARCINOGENESIS, V27, P1251, DOI 10.1093/carcin/bgi314-
dc.description.citedreferencePasquali R, 2006, FERTIL STERIL, V85, P1319, DOI 10.1016/j.fertnstert.2005.10.054-
dc.description.citedreferenceRandi G, 2006, INT J CANCER, V118, P1591, DOI 10.1002/ijc.21683-
dc.description.citedreferencePanzer C, 2006, J SEX MED, V3, P104, DOI 10.1111/j.1743-6109.2005.00198.x-
dc.description.citedreferenceHSING AW, 2006, CANC EPIDEMIOLOGY PR, P787-
dc.description.citedreferenceDhiman RK, 2006, EXPERT OPIN DRUG SAF, V5, P117, DOI 10.1517/14740338.5.1.117-
dc.description.citedreferenceBarrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457-
dc.description.citedreferencePacker BR, 2004, NUCLEIC ACIDS RES, V32, pD528, DOI 10.1093/nar/gkh005-
dc.description.citedreferenceFernandez E, 2003, INT J CANCER, V105, P408, DOI 10.1002/ijc.11083-
dc.description.citedreferencePasquali R, 2002, J ENDOCRINOL INVEST, V25, P893-
dc.description.citedreferenceGallus S, 2002, INT J CANCER, V99, P762, DOI 10.1002/ijc.10411-
dc.description.citedreferenceKamat A, 2002, TRENDS ENDOCRIN MET, V13, P122-
dc.description.citedreferenceTsuchiya Y, 2002, J EXP CLIN CANC RES, V21, P119-
dc.description.citedreferenceSchaid DJ, 2002, AM J HUM GENET, V70, P425-
dc.description.citedreferencePARKIN DM, 2002, IARC SCI PUBLICATION, V155-
dc.description.citedreferenceSimon JA, 2001, ANN INTERN MED, V135, P493-
dc.description.citedreferenceSchwarz D, 2000, PHARMACOGENETICS, V10, P519-
dc.description.citedreferenceUhler ML, 2000, MENOPAUSE, V7, P162-
dc.description.citedreferenceBartsch H, 2000, CANCER EPIDEM BIOMAR, V9, P3-
dc.description.citedreferenceLowenfels AB, 1999, HEPATO-GASTROENTEROL, V46, P1529-
dc.description.citedreferenceKhan ZR, 1999, AM J GASTROENTEROL, V94, P149-
dc.description.citedreferenceHsing AW, 1998, INT J CANCER, V75, P368-
dc.description.citedreferenceZatonski WA, 1997, J NATL CANCER I, V89, P1132-
dc.description.citedreferenceTavani A, 1996, EUR J CANCER PREV, V5, P241-
dc.description.citedreferenceFeigelson HS, 1996, J CELL BIOCHEM, P15-
dc.description.citedreferenceEXCOFFIER L, 1995, MOL BIOL EVOL, V12, P921-
dc.description.citedreferenceTAIOLI E, 1995, TOXICOL LETT, V77, P357-
dc.description.citedreferenceCHOW WH, 1994, CANCER CAUSE CONTROL, V5, P267-
dc.description.citedreferenceMOERMAN CJ, 1994, INT J CANCER, V57, P146-
dc.description.citedreferenceCOSMA G, 1993, J TOXICOL ENV HEALTH, V40, P309-
dc.description.citedreferenceMILNE R, 1991, CONTRACEPTION, V43, P667-
dc.description.citedreferenceEVERSON GT, 1991, J CLIN INVEST, V87, P237-
dc.description.citedreferenceKRITZSILVERSTEIN D, 1990, J CLIN EPIDEMIOL, V43, P687-
dc.description.citedreferenceKATO K, 1989, JPN J CANCER RES, V80, P932-
dc.description.citedreferenceYEN S, 1987, CANCER, V59, P2112-
dc.description.citedreferenceBERNSTEIN L, 1985, J NATL CANCER I, V74, P741-
dc.description.citedreferenceSIITERI PK, 1982, RECENT PROG HORM RES, V38, P457-
dc.description.citedreferenceBALL P, 1980, ACTA ENDOCRINOL S93, V232, P1-
dc.description.citedreferenceARMITAGE P, 1955, BIOMETRICS, V11, P375-
dc.description.tc6-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share